Replimune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. 

CEO
Sushil Patel
CEOSushil Patel
Employees
465
Employees465
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
465
Employees465

REPL Key Statistics

Market cap
972.09M
Market cap972.09M
Price-Earnings ratio
-3.30
Price-Earnings ratio-3.30
Dividend yield
Dividend yield
Average volume
3.76M
Average volume3.76M
High today
$11.95
High today$11.95
Low today
$11.09
Low today$11.09
Open price
$11.24
Open price$11.24
Volume
2.84M
Volume2.84M
52 Week high
$13.24
52 Week high$13.24
52 Week low
$1.50
52 Week low$1.50

Stock Snapshot

The current Replimune(REPL) stock price is $11.49, with a market capitalization of 972.09M. The stock trades at a price-to-earnings (P/E) ratio of -3.30.

As of 2026-07-05, Replimune(REPL) stock has fluctuated between $11.09 and $11.95. The current price stands at $11.49, placing the stock +3.6% above today's low and -3.9% off the high.

The Replimune(REPL)'s current trading volume is 2.84M, compared to an average daily volume of 3.76M.

In the last year, Replimune(REPL) shares hit a 52-week high of $13.24 and a 52-week low of $1.50.

In the last year, Replimune(REPL) shares hit a 52-week high of $13.24 and a 52-week low of $1.50.

REPL News

TipRanks 5d
BMO double upgrades Replimune on higher chances of FDA approval

BMO Capital double upgraded Replimune (REPL) to Outperform from Underperform with a price target of $16, up from $1. The FDA’s acceptance of Replimune’s re-file...

TipRanks 6d
Replimune Group put volume heavy and directionally bearish

Bearish flow noted in Replimune (REPL) Group with 1,899 puts trading, or 1.4x expected. Most active are Aug-26 7 puts and Aug-26 15 calls, with total volume in...

Nasdaq 6d
Replimune Group Inc. Full Year Loss Widens

(RTTNews) - Replimune Group Inc. (REPL) revealed Loss for its full year of -$313.940 million The company's bottom line totaled -$313.940 million, or -$3.38 per...

Replimune Group Inc. Full Year Loss Widens

Analyst ratings

50%

of 8 ratings
Buy
37.5%
Hold
50%
Sell
12.5%

People also own

Based on the portfolios of people who own REPL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.